Bought back a little at 69

Making a mockery of minorities again

May impact how much divvy GenM can afford to pay moving forward

Oh ya saw that, some news articles were mentioning that the piece belongs to Genting Berhad, which is also not wrong lol

Maybe some ppl bought at 2.98 selling leh?
Cash out to bring family for vacation leh?
Cash out to buy that dream house?
Don't get attached to daily price changes lah

If not mistaken, that belongs to Genting Berhad not GenM
Correct me if I'm wrong

Matched some 1.05

Take profit, moving to gloves

Depends how good can the business grow
Just sold more, holding only 10% now

Unless of course, LKT already planned this to appease to investors after losing out Macau bid? lol

Hard to say whether this is a good move
It doesn't look too bad when compared to acquiring Empire, at the very least things have improved
Still, just having ebitda positive is not good enough, at least on the interest portion
Its a minor negative to me now that Macau is off the hook

Queued

Re-openings are starting to happen
I read that one area already not required masking

10 sen divvy for Q4 I'd be happy enough

Sold half

Vroooom

FIRL
https://www.youtube.com/watch?v=wJWypNFuh3U

https://www.fiercebiotech.com/biotech/roche-thins-alzheimers-program-after-phase-3-failure-may-seek-external-partnerships

I always only see/hear Roche and Biogen news, rarely on Taurx, kinda wonder why
Perhaps Roche can partner Taurx for an early value unlocking? lol

Monday market will tell its opinion

If it is not possible to have plausible placebo, how to perform proper trial?

So what now, another trial?

Trial was the failure, probably not the drug

"In addition, the results are hard to interpret without proper placebo controls. There are many unanswered questions," she said.

Aaron Burstein, PharmD, head of search and evaluation at the Alzheimer's Drug Discovery Foundation, agreed in an interview that the findings are difficult to interpret.

On one hand, it's a negative study, he said. However, "one could question, was it actually a failed trial considering the results?"

Gist of the report

However, the "bottom line" regarding the TauRx data is that "this was a negative trial. There wasn't a difference between the low-dose, originally intended as the placebo/comparison group, and high-dose groups," said Snyder.

https://www.medscape.com/viewarticle/984863

Buyback some 6.02

Yesterday and today was flushing weak holders?

Seems like no more vroooom

The shark is still in the water

Tomorrow can get free

Come on Natsuko, don't be too lazy to update the TP, why same in all glove counter forums

If GenM won Macau, you can kiss dividend good bye or it will be lowered for at least a few years
Better to focus on existing business improvement for better sales and margin

Don't be too optimistic, slow and steady up is good

Seems like 1.10 is the fair value based on market trading

Sold those bought during election slump after Anwar won
Now buyback

Bought some

That's what I don't like about these drug process, mid 2023 for 24 month review. Hopefully the approval criteria don't need to wait for 36, 48, 60 month review

Recently pharma counters have some uptick, can count Genting in? lol

BUY GENTING FOR HEALTH
How? Eh sai boh?

This is bot trading going on, can be outwit

Almost matched at 6.01 lol
Could've bought another round at 6.02

Buyback a little 6.08

Looking attractive now

Will be tough to go to eighth floor

Tonight Taurx having their turn to talk in CTAD

If manage to sell off, one off gain huge on next QR

Selling the piece of land is a big plus, rushing to 4.50 now...

Hand itchy, sold another 8% lol

Vrooooooomssssss

80 sen by year end?